Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care

Journal of Clinical Psychopharmacology

Volumn 30, Issue 6, 2010, Pages 746-748

  Reis, Margareta ^a   Åkerblad, Ann Charlotte ^b   Ekselius, Lisa ^b   Von Knorring, Lars ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SERTRALINE;

ADULT; AGED; CLINICAL GLOBAL IMPRESSION SCALE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG MONITORING; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PRIMARY HEALTH CARE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; YOUNG ADULT;

EID: 78649378605     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181fc2cf1     Document Type: Letter

References (16)

1. Frank E, Perel JM, Mallinger AG, et al. Relationship of pharmacologic compliance to long-term prophylaxis in recurrent depression. Psychopharmacol Bull. 1992;28(3):231-235.
2. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128-1132.
3. Akerblad AC, Bengtsson F, von Knorring L, et al. Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol. 2006;21(2):117-124.
4. Gopinath S, Katon WJ, Russo JE, et al. Clinical factors associated with relapse in primary care patients with chronic or recurrent depression. J Affect Disord. 2007;101(1-3):57-63.
5. Noble L. Doctor-Patient Communication and Adherence to Treatment, in Adherence to Treatment in Medical Conditions. Myers L, Midence K, eds. London: Wiley; 1998:51-82.
6. Demyttenaere K, Enzlin P, Dewé W, et al. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(suppl 22):30-33.
7. Cantrell CR, Eaddy MT, Shah MB, et al. Methods for evaluating patient adherence to antidepressant therapy: a real-world comparison of adherence and economic outcomes. Med Care. 2006;44(4):300-303.
8. Olfson M, Marcus SC, Tedeschi M, et al. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101-108.
9. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37(6):243-265.
10. Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? Eur Arch Psychiatry Clin Neurosci. 2008;258(suppl 1):21-27.
11. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiatry. 1991;52(suppl 8):23-33.
12. Reis M, A? berg-Wistedt A, A? gren H, et al. Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disord. 2004;82(3):443-446.
13. A? kerblad AC, Bengtsson F, Ekselius L, et al. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. Int Clin Psychopharmacol. 2003;18(6):347-354.
14. Montgomery SA, A? sberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134: 382-389.
15. Guy W. Clinical Global Impression, in ECDEU Assessment Manual for Psychopharmacology. Rev. Rockville, MD: National Institute of Health, Psychopharmacology Research Branch; 1976.
16. Björk H, Bengtsson F. A simple method for routine TDM of the SSRI sertraline and desmethylsertraline in serum by HPLC. Eur J Clin Pharmacol. 1997;52(suppl):A156.